Revised. Amendments from Version 1
==================================

The following modifications have been made in the newest version: All the gene acronyms were re-written italics;  Table S2 was an assessment standard for included articles but the assessment scores were not included in our article, we explained this matter in Materials and methods \-- Methodological quality assessment；  Page 6, Figure 1, Eligibility section, the number of full-text articles excluded with reasons were corrected with 5;  The publication bias analysis when \< 10 articles is not statistically resolved (see Egers\'s paper), so a comment about this issue was added in Results \-- Sensitivity analysis and publication bias and the fourth paragraph in Discussion  In order to reduce the repeat content in the first two paragraph of Discussion and Introduction, we deleted several sentences in the Discussion;  In the third paragraph of Discussion, a description of the controversial conclusions of included studies was made to make the discussion more interesting.  Based on our result, we deeply explained our conclusion and put out suggestion about sample taking in future studies in the last paragraph.

Introduction
============

Cleft of the lip and/or palate (CL/P) is one of the most common facial malformations ^[@ref-1]--\ [@ref-3]^ and a societal burden, affecting the patient ability to eat and speak and influencing social integration ^[@ref-4]^. Non-syndromic CL/P, accounting for about 70% of CL/P, is considered closely related to genetic and environmental factors ^[@ref-5]^. Recent studies suggested that using folic acid could reduce the rates of oral clefts ^[@ref-6],\ [@ref-7]^ and single nucleotide polymorphisms of some genes such as MTHFR ^[@ref-8],\ [@ref-9]^, MTR ^[@ref-40]^ and MTRR involved in the metabolism of folic acid have been associated to high risk of NSCL/P ^[@ref-8],\ [@ref-9]^. Methylenetetrahydrofolate dehydrogenase 1 ( *MTHFD1*), a key gene associated with three sequential enzymatic reactions in the metabolism of folic acid, might play a potential role in the risk of NSCL/P, especially the polymorphism rs2236225 (c.1958G\>A) ^[@ref-10]^. Indeed, different observations that linked the polymorphism rs2236225 to the risk of NSCL/P have been reported ^[@ref-11],\ [@ref-12]^. The suggestion of a link between rs2236225 polymorphism and susceptibility to NSCL/P might be result of the limitations in sample size, different ethnic populations and other environmental factors. Therefore, we conducted a systematic review and meta-analysis of eligible case-control studies to reveal a more precise connection between the *MTHFD1* polymorphism rs2236225 and the risk of NSCL/P.

Materials and methods
=====================

Identification of studies
-------------------------

A systematic search based on the principle of evidence-based medicine ^[@ref-13]^ was performed in PubMed, Web of Science, Cochrane Library, Google Scholar, China National Knowledge Infrastructure (CNKI) and WanFang Database. The final update was made on April 5th, 2015. In line with our knowledge background, the Medical Subject Headings (MESH) terms in PubMed and the known aliases of the genes of interests in the National Center of Biotechnology Information (NCBI), the following terms were used for searching: "cleft lip OR cleft palate OR CLP OR CL/P OR oral facial cleft OR OFC" AND "methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 OR methenyltetrahydrofolate cyclohydrolase formyltetrahydrofolate synthetase OR *MTHFD1* OR MTHFD", which were slightly adjusted to optimize search results ( [Table S1](#TS1){ref-type="other"}; PubMed). We didn't limit the search depending on publication types, data and language. Of course, the review of the published literature was examined carefully and manual search was conducted to avoid missing potential data. Two of the authors (Huaxiang Zhao and Mengqi Zhang) were in charge of the search independently and a third author (Jieni Zhang) conducted a random inspection.

Inclusion and exclusion criteria
--------------------------------

Researches included in our systematic review and meta-analysis meet the following criteria: (1) evaluating the association between the NSCL/P and *MTHFD1* polymorphism rs2236225, (2) focusing on humans, (3) case-control studies. Exclusion criteria were: (1) no association between NSCL/P and MTFHD1, (2) not focusing on humans but animal models or *in vitro* studies, (3) duplication of previous researches, (4) not original literature such as reviews, meta-analyses, comments and editorials.

Data collection
---------------

Data from eligible studies were extracted by two independent researchers (Huaxiang Zhao and Mengqi Zhang) in accordance with the inclusion and exclusion criteria. In case of any discrepancies, the third chief author (Feng Chen) would make a further investigation or bring it into a group-discussion. A special table was used for collecting information from the selected articles and the following entries were recorded: authors (year), country, location of geography, subjects, methods for genotyping, sample size of cases/controls, descriptions of samples rolled in the study, P for HWE (Hardy-Weinberg equilibrium) of control group, whether included in the meta-analysis or not.

Methodological quality assessment
---------------------------------

A methodological quality assessment adapted from previous studies ^[@ref-14]--\ [@ref-16]^ was carried on included studies ( [Table S2](#TS2){ref-type="table"}). Cases, source of controls, sample sizes and Hardy-Weinberg equilibrium (HWE) were considered as important aspects in this systematic review. It is not a widely-used standard so its efficiency is not certain. The result does not include the judgments but the standard can be a reference for the certainty of conclusion.

Statistical analysis
--------------------

The PRISMA checklist ( [Supplementary material S3](#TS3){ref-type="other"}) was used as a protocol in our meta-analysis ^[@ref-17]^. Odd ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the association between the susceptibility to NSCL/P and *MTHFD1*. Five genetic models were used in the process of pooling the OR and 95% CIs: allelic comparison (A versus G), heterozygote model (AG versus GG), homozygote model (AA versus GG), dominant model (AA + AG versus GG), recessive model (AA versus AG + GG). The significance of the pooled effects was determined by Z-test with P value less than 0.05. The Q-statistic and the I ^2^ test were used to evaluated; P \< 0.05 in Q statistic or I ^2^ \> 50% ^[@ref-18],\ [@ref-19]^, would indicate a significant heterogeneity. When P \> 0.05 in Q statistic or I ^2^ \< 50%, the fixed pooling model (Mantel-Haenszel) was conducted; if not, the random pooling model (M-H heterogeneity) was used. We also carried subgroup analyses in which different subjects (mothers or children), location of geography (non-Asian countries or Asian countries) were considered potential source of heterogeneity. A sensitivity analysis was conducted by omitting each study in turn to evaluate the single study's influence on the overall estimation. We used Begg's funnel plot and Egger's linear regression test to find out the publication bias of the included studies ^[@ref-20]--\ [@ref-22]^. The studies with disequilibrium of HWE among control group were added into a supplementary meta-analysis as described previously ^[@ref-23]^. Meanwhile, as for the studies included but not carried into the meta-analysis, to achieve a qualitative analysis we adopted a method described by others ^[@ref-24]^. Results were considered significant when P \< 0.05. Stata 12.0 (Stata Corp, College Station, TX, USA) was used for the analysis.

Results
=======

Data retrieval
--------------

A total of 251 articles resulted from the search described above (PubMed: 86, Web of Science: 8, Google Scholar: 135, Cochrane Library: 0, CNKI: 18, Wanfang: 4). After being imported into EndNote X6 software (Thomson Corporation, Stamford), a screening process was conducted among 102 articles-- that is, duplicates were removed using the 'Discard Duplicates' function as well as by handwork. Following paper selection by two independent researchers, 15 studies were then thoroughly reviewed. Of these, five studies were excluded, among which two had no control groups ^[@ref-25],\ [@ref-26]^, one no relation to MTFHD1 ^[@ref-27]^, and the other two presented data previously published ^[@ref-28],\ [@ref-29]^. Finally, 10 studies that met the criteria were included in the systematic review ( [Table 1](#T1){ref-type="table"}) ^[@ref-10]--\ [@ref-12],\ [@ref-30]--\ [@ref-36]^ and mathematic data from eight studies were used for reference to carry out the meta-analysis ^[@ref-10]--\ [@ref-12],\ [@ref-31]--\ [@ref-33],\ [@ref-35],\ [@ref-36]^. The selection process is shown in [Figure 1](#f1){ref-type="fig"}.

###### Characteristics of studies included in the systematic review and meta-analysis.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   Authors (year)        Country   Geographical\   Subjects    Methods for\                                Sample size of\    Descriptions of\      P for\                      Whether\                              
                                        location                    genotyping                                  case/control\      samples from study\   HWE\* of\                   included\                             
                                                                                                                group (just for\   participants          control\                    in meta-\                             
                                                                                                                the patients)                            group                       analysis\                             
                                                                                                                                                                                     or not                                
  ----- --------------------- --------- --------------- ----------- ------------------------------------------- ------------------ --------------------- --------------------------- ------------------------------------- -----
  1     Mostowska *et al.*\   Poland    Europe          Mothers     PCR-RFLP ^[γ](#note-1){ref-type="other"}^   122                82                    The case samples\           NM ^[ψ](#note-2){ref-type="other"}^   Yes
        (2006)                                                                                                                                           came from healthy\                                                
                                                                                                                                                         mothers of NSCL/P\                                                
                                                                                                                                                         children, while the\                                              
                                                                                                                                                         control group includes\                                           
                                                                                                                                                         samples from healthy\                                             
                                                                                                                                                         mothers of children\                                              
                                                                                                                                                         without NSCL/P. There\                                            
                                                                                                                                                         was no difference\                                                
                                                                                                                                                         between the two\                                                  
                                                                                                                                                         groups in their age,\                                             
                                                                                                                                                         habit of smoking.                                                 

  2     Boyles *et al.*\      Norway    Europe          Mothers\    MALDI-TOF\                                  573                763                   377 cases were CL/P\        NM ^[ψ](#note-2){ref-type="other"}^   No
        (2008)                                          and\        MS ^[ξ](#note-3){ref-type="other"}^                                                  and 196 cases CPO.\                                               
                                                        children                                                                                         Most mothers in\                                                  
                                                                                                                                                         the case group use\                                               
                                                                                                                                                         supplemental folate\                                              
                                                                                                                                                         during the pregnancy.                                             

  3     Mills *et al.*\       Ireland   Europe          Mothers,\   PCR-RFLP ^[γ](#note-1){ref-type="other"}^   1030               1000                  536 were CLP\               0.03                                  Yes
        (2008)                                          fathers\                                                                                         consisted of 494 cases\                                           
                                                        and\                                                                                             with isolated defects\                                            
                                                        children                                                                                         23 with one additional\                                           
                                                                                                                                                         defect, 18 with multiple\                                         
                                                                                                                                                         defects, and one with\                                            
                                                                                                                                                         Pierre Robin. 426 cases\                                          
                                                                                                                                                         with CPO consisted of\                                            
                                                                                                                                                         321 isolated defects,\                                            
                                                                                                                                                         15 with one additional\                                           
                                                                                                                                                         defect, 21 with multiple\                                         
                                                                                                                                                         defects, and 69 with\                                             
                                                                                                                                                         Pierre Robin Sequence.                                            

  4     Bufalino *et al.*\    Brazil    South America   Mothers     PCR-RFLP ^[γ](#note-1){ref-type="other"}^   106                184                   Mothers who smoke,\         0.66                                  Yes
        (2010)                                                                                                                                           drink and use anti-\                                              
                                                                                                                                                         hypertensives and\                                                
                                                                                                                                                         drugs that could\                                                 
                                                                                                                                                         potentially impair the\                                           
                                                                                                                                                         function of folic acids\                                          
                                                                                                                                                         were not included in\                                             
                                                                                                                                                         this study.                                                       

  5     Mostowska *et al.*\   Poland    Europe          Children    PCR-RFLP ^[γ](#note-1){ref-type="other"}^   174                176                   The patients with clefts\   0.11                                  Yes
        (2010)                                                                                                                                           palate only (CPO) were\                                           
                                                                                                                                                         excluded because the\                                             
                                                                                                                                                         researchers thought\                                              
                                                                                                                                                         the pathogenesis of\                                              
                                                                                                                                                         NSCL/P and the CPO\                                               
                                                                                                                                                         was different.                                                    

  6     Li *et al.* (2013)    China     Asian           Children    PCR-RFLP ^[γ](#note-1){ref-type="other"}^   187                157                   The patients in the case\   0.89                                  Yes
                                                                                                                                                         group consisted of 126\                                           
                                                                                                                                                         boys and 61 girls.                                                

  7     Yuan (2013)           China     Asian           Mothers,\   PCR-RFLP ^[γ](#note-1){ref-type="other"}^   150                150                   68 CLO and 82 CLP\          0.92                                  Yes
                                                        fathers\                                                                                         were enrolled in the\                                             
                                                        and\                                                                                             case group.                                                       
                                                        children                                                                                                                                                           

  8     Zhao *et al.*\        China     Asian           Children    PCR-RFLP ^[γ](#note-1){ref-type="other"}^   294                126                   There were 191 CLP\         0.08                                  Yes
        (2013)                                                                                                                                           and 103 CPO in the\                                               
                                                                                                                                                         patients group.                                                   

  9     de Aquino *et al.*\   Brazil    South America   Mothers,\   Real-Time\                                  181                478                   Patients with clefts\       NM ^[ψ](#note-2){ref-type="other"}^   No
        (2013)                                          fathers\    PCR                                                                                  palate only (CPO) were\                                           
                                                        and\                                                                                             excluded. 65 clefts lip\                                          
                                                        children                                                                                         only (CLO) and 116\                                               
                                                                                                                                                         clefts lip and palate\                                            
                                                                                                                                                         (CLP) were included in\                                           
                                                                                                                                                         this study, consisting\                                           
                                                                                                                                                         of 101 males and 80\                                              
                                                                                                                                                         females.                                                          

  10    Murthy *et al.*\      India     Asian           Children    PCR-RFLP ^[γ](#note-1){ref-type="other"}^   142                141                   There were 123 CLP\         0.94                                  Yes
        (2014)                                                                                                                                           and 19 CPO in the case\                                           
                                                                                                                                                         group.                                                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HWE\*: Hardy-Weinberg equilibrium.

NM ^ψ^: Not mentioned in the study.

PCR-RFLP ^γ^: PCR-restriction fragment length polymorphism.

MALDI-TOF MS ^ξ^: matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

![Flow chart showing study selection in the systematic and meta-analysis.](f1000research-4-7371-g0000){#f1}

Study characteristics
---------------------

Eventually, all 10 studies containing 6216 samples (2959 cases and 3257 controls) were analyzed in our review. The characteristics of every study can be seen in [Table 1](#T1){ref-type="table"}. To summarize briefly, there were four studies from European groups, four from Asian groups and two from South American groups, among which two studies focused on the genotype of patients' mothers only, four on children' s genotype only and four on both of them. PCR-restriction fragment length polymorphism (PCR-RFLP) was the major method of genotyping, while other techniques had been used as well.

Association between *MTHFD1* polymorphism rs2236225 (c.1958G\>A) and NSCL/P susceptibility
------------------------------------------------------------------------------------------

The association between *MTHFD1* polymorphism rs2236225 (c.1958G\>A) and NSCL/P susceptibility was analyzed through a meta-analysis and qualitative analysis. In the meta-analysis, since significant heterogeneity had been identified by Q-test and I ^2^ statistic in every genetic model, the random effect models were used. Overall, a significant association was not found in any genetic model (A versus G: OR = 1.02, 95% CI 0.86--1.21, P ~H~ = 0.010, [Figure 2](#f2){ref-type="fig"}; AG versus GG: OR = 0.97, 95% CI 0.75--1.26, P ~H~ = 0.019, [Figure 3A](#f3){ref-type="fig"}; AA versus GG: OR = 1.07, 95% CI 0.70--1.65, P ~H~ = 0.005, [Figure 3B](#f3){ref-type="fig"}; AA + AG versus GG: OR = 1.00, 95% CI 0.76--1.31, P ~H~ = 0.006, [Figure 3C](#f3){ref-type="fig"}; AA versus AG + GG: OR = 1.05, 95% CI 0.71--1.53, P ~H~ = 0.014, [Figure 3D](#f3){ref-type="fig"}). On the other hand, no association was found in the genotypes of children, mothers or fathers in the qualitative analysis ^[@ref-30],\ [@ref-34]^.

![Forest plot of allelic comparison of *MTHFD1* polymorphism rs2236225 (c.1958G\>A) for overall comparison (A versus G).](f1000research-4-7371-g0001){#f2}

![Forest plot of heterozygote, homozygote, dominant and recessive model comparison of *MTHFD1* polymorphisms rs2236225 (c.1958G\>A) for overall comparison.\
( **A**) Heterozygote model, AG versus GG. ( **B**) Homozygote model, AA versus GG. ( **C**) Dominant model, AA + AG versus GG. ( **D**) Recessive model, AA versus AG + GG.](f1000research-4-7371-g0002){#f3}

Next we conducted the subgroup analysis using allelic A versus G model according to the location of geography and subjects (mothers or children). It turned out that there was no significant difference between Asian (OR = 1.03, 95% CI 0.75--1.40, P ~H~ = 0.003) or non-Asian population (OR = 1.06, 95% CI 0.86--1.30, P ~H~ = 0.118). However, a higher degree of heterogeneity was observed in the Asian countries compared to non-Asian countries ( [Figure 4A](#f4){ref-type="fig"}). A similar result was observed in the subgroup analysis between mothers and children. The heterogeneity was much higher in the children group (OR = 0.99, 95% CI 0.72--1.36, P ~H~ = 0.001) than in the mothers' group (OR = 1.11, 95% CI 0.98--1.27, P ~H~ = 0.630), while no significant difference was observed in both groups ( [Figure 4B](#f4){ref-type="fig"}).

![Subgroup analysis by locations of geography ( **A**) and subjects ( **B**) under allelic comparison of *MTHFD1* polymorphism rs2236225 (c.1958G\>A).](f1000research-4-7371-g0003){#f4}

Sensitivity analysis and publication bias
-----------------------------------------

To access the influence of each individual study on the pooled ORs, a sensitivity analysis was performed by omitting each study at a time. The results of sensitivity suggests that no individual study affects the pooled ORs of the associations between *MTHFD1* polymorphism rs2236225 (c.1958G\>A) and NSCL/P risk under allelic model ( [Figure 5](#f5){ref-type="fig"}).

![Sensitivity analysis of the association between *MTHFD1* polymorphism rs2236225 (c.1958G\>A) and susceptibility to NSCL/P under allelic model (A versus G).](f1000research-4-7371-g0004){#f5}

We used the Begg's funnel plot and Egger's regression test (both used the allelic A versus G model) to estimate the publication bias. Our results indicate that there is no significant publication bias both in the symmetry of Begg's funnel plot (P = 0.711, [Figure 6](#f6){ref-type="fig"}) and Egger's regression test (P = 0.746). But due to the sample size (the total number of included article is less than 10), statistical analyses may not describe the publication bias precisely. The test reliability is in doubt.

![Begg's funnel plot of the association between *MTHFD1* polymorphism rs2236225 (c.1958G\>A) and the susceptibility to NSCL/P under allelic model (A versus G).](f1000research-4-7371-g0005){#f6}

Discussion
==========

CL/P is one of the most common facial malformations, affecting approximately 1.7/1000 people around the world with ethnic and geographic variation ^[@ref-1]^. Approximately 70% of CL/P cases are considered to be non-syndromic ^[@ref-37],\ [@ref-38]^, and their susceptibility has been linked to the expression of various candidate genes through twin studies, familial clustering studies and genome-wide studies ^[@ref-39]^. Recent studies suggest that using folic acid could reduce the rates of oral clefts ^[@ref-6],\ [@ref-7]^ and genes involved in the metabolish of folic acid have been identified *MTHFD1*, a crucial gene associated with three sequential enzymatic reactions among 5,10-methylenetetrahydrofolate, 5,10-methenyltetrahydrofolate, 10-formyltetrahydrofolate, tetrahydrofolate, might play a potential role in NSCL/P ^[@ref-10]^. However, controversial results about the *MTHFD1* polymorphism rs2236225 (c.1958G\>A) have been reported in different articles ^[@ref-10],\ [@ref-12]^.

In this systematic review, 10 independent case-control studies were included (eight studies for meta-analysis and two studies qualitatively analyzed) containing 6216 samples (2959 cases and 3257 controls). In all of the included 8 studies for meta-analysis, 7 did not show significant difference between the case and control groups. 1 study reported that the case group showed closer relationship with *MTHFD1* polymorphisms rs 2236225 (c.1958G\>A). After the over-all analysis we concluded the comprehensive effect. All the eligible studies of meta-analysis and qualitative analysis showed no significant association of *MTHFD1* rs2236225 to the risk of NSCL/P, whether in the whole analysis of five model (A versus G, AG versus GG, AA versus GG, AA + AG versus GG, AA versus AG + GG) or in the subgroup of subjects (mothers or children) and the location of geography (non-Asian countries or Asian countries). Meanwhile, high heterogeneity was observed, which might be the reason for the genetic drift and natural selection among different ethnic groups ^[@ref-42]^. Also, small sample size of different studies might be a possible reason for the disparate results. Our findings suggest that the *MTHFD1* polymorphism rs2236225 (c.1958G\>A) might not be an appropriate biomarker in predicting the susceptibility of an individual to NSCL/P.

Some limitations of this systematic review and meta-analysis should be noted. Firstly, the choice of retrospective studies has its own limitations, as we may encounter selection bias and influence the results of our analysis ^[@ref-43]^. However, a bigger size of cohort study cannot be conducted easily because of the relatively low morbidity ^[@ref-44]^. Secondly, only 10 studies were included in our review, a small sample size that might not provide sufficient evidence to estimate the connections between the *MTHFD1* polymorphisms and the risk of NSCL/P. Thirdly, the publication bias cannot be effectively analyzed because of the limited amount of included study.

NSCL/P is also associated with gene-gene and gene-environment interactions ^[@ref-45]^. Although no correlation was observed between MTFHD1 polymorphism rs2236225 (c.1958G\>A) and the risk of NSCL/P, in view of MTFHD1 gene's key role in folic acid metabolism, we cannot draw a definite conclusion that there is no association between MTFHD1 and NSCL/P's susceptibility. The use of larger sample size studies, different techniques and considering gene-gene or gene-environment interactions should be explored in future investigations. What is more, the gene samples from mother were too scarce to be representative and to explain our results. We do recommend more samples from parents in the future studies, which is significant for the early stage diagnose, as the current technology can only diagnose CLP in the midterm even later in the pregnancy.

Supplementary materials
=======================

###### Typical search terms used in Pubmed.

  ------ ---------------------------------------------------------------------------
  \#1    cleft lip
  \#2    cleft palate
  \#3    cleft lip and palate
  \#4    cleft lip and/or palate
  \#5    CLP
  \#6    CL/P
  \#7    oral facial cleft
  \#8    OFC
  \#9    methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1
  \#10   methenyltetrahydrofolate cyclohydrolase formyltetrahydrofolate synthetase
  \#11   *MTHFD1*
  \#12   *MTHFD*
  \#13   *MTHFC*
  \#14   \#1 OR \#2 OR \#3 OR \#4 OR \#5 OR \#6 OR \#7 OR \#8
  \#15   \#9 OR \#10 OR \#11 OR \#12 OR \#13
  \#16   \#14 AND \#15
  ------ ---------------------------------------------------------------------------

###### Scale for methodological quality assessment.

  Items                                                                   Score
  ----------------------------------------------------------------------- -------
  1.  Representative cases                                                
       NSCL/P diagnosed by acknowledged criteria.                         2
       Mentioned the diagnosed criteria but not described specifically.   1
       Not Mentioned.                                                     0
  2.  Source of controls                                                  
       Population or community-based                                      2
       Hospital-based                                                     1
       Not described                                                      0
  3.  Sample size                                                         
       \>300                                                              2
       150--300                                                           1
       \<150                                                              0
  4.  Hardy-Weinberg equilibrium (HWE)                                    
       Hardy-Weinberg equilibrium in control group                        1
       Hardy-Weinberg disequilibrium in control group                     0

###### PRISMA checklist used for protocol (available at <http://www.prisma-statement.org/statement.htm>).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Section/topic            \#   Checklist item                                                                              Reported on\
                                                                                                                            page \#
  ------------------------ ---- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------
  Title                                                                                                                     

  Title                    1    Identify the report as a systematic review, meta-analysis, or both.                         1

  **Abstract**                                                                                                              

  Structured summary       2    Provide a structured summary including, as applicable: background; objectives;\             2\~3
                                data sources; study eligibility criteria, participants, and interventions; study\           
                                appraisal and synthesis methods; results; limitations; conclusions and implications\        
                                of key findings; systematic review registration number.                                     

  **Introduction**                                                                                                          

  Rationale                3    Describe the rationale for the review in the context of what is already known.              4

  Objectives               4    Provide an explicit statement of questions being addressed with reference to\               5
                                participants, interventions, comparisons, outcomes, and study design (PICOS).               

  **Methods**                                                                                                               

  Protocol and\            5    Indicate if a review protocol exists, if and where it can be accessed (e.g., Web\           none
  registration                  address), and, if available, provide registration information including registration\       
                                number.                                                                                     

  Eligibility criteria     6    Specify study characteristics (e.g., PICOS, length of follow-up) and report\                5\~6
                                characteristics (e.g., years considered, language, publication status) used as\             
                                criteria for eligibility, giving rationale.                                                 

  Information sources      7    Describe all information sources (e.g., databases with dates of coverage, contact\          5
                                with study authors to identify additional studies) in the search and date last\             
                                searched.                                                                                   

  Search                   8    Present full electronic search strategy for at least one database, including any\           [Table S1](#TS1){ref-type="table"}
                                limits used, such that it could be repeated.                                                

  Study selection          9    State the process for selecting studies (i.e., screening, eligibility, included in\         5\~6
                                systematic review, and, if applicable, included in the meta-analysis).                      

  Data collection\         10   Describe method of data extraction from reports (e.g., piloted forms,\                      5\~6
  process                       independently, in duplicate) and any processes for obtaining and confirming data\           
                                from investigators.                                                                         

  Data items               11   List and define all variables for which data were sought (e.g., PICOS, funding\             5\~6
                                sources) and any assumptions and simplifications made.                                      

  Risk of bias in\         12   Describe methods used for assessing risk of bias of individual studies (including\          6 and [Table S2](#TS2){ref-type="other"}
  individual studies            specification of whether this was done at the study or outcome level), and how this\        
                                information is to be used in any data synthesis.                                            

  Summary measures         13   State the principal summary measures (e.g., risk ratio, difference in means).               6\~7

  Synthesis of results     14   Describe the methods of handling data and combining results of studies, if done,\           6\~7
                                including measures of consistency (e.g., I ^2^) for each meta-analysis.                     

  Risk of bias across\     15   Specify any assessment of risk of bias that may affect the cumulative evidence\             6\~7
  studies                       (e.g., publication bias, selective reporting within studies).                               

  Additional analyses      16   Describe methods of additional analyses (e.g., sensitivity or subgroup analyses,\           7
                                meta-regression), if done, indicating which were pre-specified.                             

  **Results**                                                                                                               

  Study selection          17   Give numbers of studies screened, assessed for eligibility, and included in the\            8 and [Figure 1](#f1){ref-type="fig"}
                                review, with reasons for exclusions at each stage, ideally with a flow diagram.             

  Study characteristics    18   For each study, present characteristics for which data were extracted (e.g., study\         [Table 1](#T1){ref-type="table"}
                                size, PICOS, follow-up period) and provide the citations.                                   

  Risk of bias within\     19   Present data on risk of bias of each study and, if available, any outcome level\            9\~10, [Table S2](#TS2){ref-type="other"}
  studies                       assessment (see item 12).                                                                   

  Results of individual\   20   For all outcomes considered (benefits or harms), present, for each study: (a) simple\       [Figure 2](#f2){ref-type="fig"}
  studies                       summary data for each intervention group (b) effect estimates and confidence\               
                                intervals, ideally with a forest plot.                                                      

  Synthesis of results     21   Present results of each meta-analysis done, including confidence intervals and\             [Figure 2](#f2){ref-type="fig"}\~ [Figure 4](#f4){ref-type="fig"}
                                measures of consistency.                                                                    

  Risk of bias across\     22   Present results of any assessment of risk of bias across studies (see Item 15).             [Table S2](#TS2){ref-type="table"}, [Figure 5](#f5){ref-type="fig"}\~\
  studies                                                                                                                   [Figure 6](#f6){ref-type="fig"}

  Additional analysis      23   Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses,\      [Figure 5](#f5){ref-type="fig"}\~ [Figure 6](#f6){ref-type="fig"}
                                meta-regression \[see Item 16\]).                                                           

  **Discussion**                                                                                                            

  Summary of evidence      24   Summarize the main findings including the strength of evidence for each main\               11\~12
                                outcome; consider their relevance to key groups (e.g., healthcare providers,\               
                                users, and policy makers).                                                                  

  Limitations              25   Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level\   12
                                (e.g., incomplete retrieval of identified research, reporting bias).                        

  Conclusions              26   Provide a general interpretation of the results in the context of other evidence, and\      13
                                implications for future research.                                                           

  **Funding**                                                                                                               

  Funding                  27   Describe sources of funding for the systematic review and other support (e.g.,\             15
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The current version of this report has properly included all of my suggestions and comments. I think that now this version was really improved the message for the readers.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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In general terms, this article contributes to unraveling the complex genetic architecture of NSCL/P. This type of systematic reviews are always relevant due to the fact that they pooled several singles trials, and therefore, the sample sizes have an important increase. However, this article needs some modifications that avoid to be published in its current version: All of the gene acronyms may be written italics.The title says \"Is MTHFD1 polymorphisms\...\" but it refers to only one SNP.The Materials and Method section includes the quality analysis of each paper included in this meta-analysis, but Results section did not mentioned anything about this analysis.The publication bias analysis when \< 10 articles is not statistically resolved (see Egers\'s paper), so for this meta-analysis it is necessary at least a comment about this issue.The first two paragraph of the Discussion section are almost the same as the Introduction.I think that the Discussion could include a comment about maternal genotype effects in order to explain the negative results of this analysis.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
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Thank you so much for your precious advice. We have studied your comments carefully and revised the manuscript. The point to point responds are listed as following: We have corrected all the inappropriate format of gene acronyms;Our title says "Is MTHFD1 polymorphisms rs 2236225 (c.1958G\>A)...", which refers to a specific SNP in accordance with the content;The traditional meta-analysis focuses on the clinical RCTs, which aims to reveal the relevance between specific interruption and clinical effects. A complete assessment standard for the included RCT reports has been widely accepted and used. While our study material is totally different from RCTs thus there is no clear assessment standard to refer. So we do not discuss the quality analysis. But in order to provide the readers an assessment standard we provide the tables 2 in supplementary materials for reference.We agree that the usual method to evaluate publication bias is not suitable for our study because of the limited amount, which reduces the reliability of our conclusion. We have declared that in the discussion of our updated version.Actually the Discussion is an overview of the article, which includes and further explains the content above. While in avoidance of repetition we modified and simplified the first and second paragraph of the Discussion.Two of our included studies only analyzed the maternal genotype, one study reported the mother and children genotype and three took samples from children and their parents. The gene samples from mother were too scarce to be representative and to explain our results. We do recommend more samples from parents in the future studies, which is significant for the early stage diagnose, as the current technology can only diagnose CLP in the midterm even later in the pregnancy.
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Non-syndromic cleft of the lip and/or palate (NSCL/P) is considered closely related to genetic and environmental factors. As a key gene in the metabolism of folic acid which is associated to high risk of NSCL/P, methylenetetrahydrofolate dehydrogenase (MTHFD1) polymorphisms rs 2237225 (c. 1958G\>A) may be associated with the susceptibility of NSCL/P. However, controversial conclusions on this association have been reported by different groups. This paper conducted a systematic review and meta-analysis of eligible case-control studies which is necessary before we go forward to larger sample size studies.

This paper is scientifically sound, clear and well-organized. However, these following revisions may make it more interesting. Page 6, Figure 1, Eligibility section, the number of full-text articles excluded with reasons should be 5.The lack of folic acid will result in many health problems such as neural tube defects, macrocytic anemia, mental depress and so on, not only NSCL/P. MTHFD1 is important in the metabolism of folic acid. Why is it suggested that MTHFD1 polymorphisms may be associated with the susceptibility of NSCL/P, but not neural tube defects ( [Meng *et al.,*2015](http://www.ncbi.nlm.nih.gov/pubmed/25524527)) or other diseases ( [Weiner *et al.*, 2014](http://www.ncbi.nlm.nih.gov/pubmed/24268703); [Silva *et al.*, 2011](http://www.ncbi.nlm.nih.gov/pubmed/21537707))?It is mentioned in the Discussion section that controversial results about the MTHFD1 polymorphism rs2236225 (c. 1958G\>A) have been reported in different articles. A brief description about the controversial results and their conclusions will make the discussion more interesting.MTHFR, MTR, AND MTRR which are involved in the metabolism of folic acid are reported to be associated with high risk of NSCL/P. Why MTHFD1 which is also involved in the metabolism of folic acid shows no significant association with susceptibility to NSCL/P? It's due to the sample size or the limit of technique, or it is the truth? A brief discussion on this will be interesting.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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Thank you. We have studied your valuable comments and revised the manuscript according to your suggestions. The point to point responds are listed as following: We have corrected the error, thank you;Neural tube defects and NSCL/P is similar in the origin of development, while the different relationship with MTHFD1 may suggest the different pathogenesis. Maybe each part of organ has a specific different folic acid metabolic pathway in their development.We are so glad to follow your advice. In all of the included 8 studies, 7 did not show significant difference between the case and control groups. 1 study reported the case group showed closer relationship with MTHFD1 polymorphisms rs 2236225 (c.1958G\>A). A brief description of this controversy is also included in this article.All 10 studies containing 6216 samples (2959 cases and 3257 controls) were analyzed in our article. Limited to the size of simple, our result cannot give a certain conclusion about the relationship of MTHFD1 and NSCL/P and won't deny the possibility of an actual relationship. The heterogeneity exists in the research method, sample source area and maternal or children genotypes. The incident rate and clinical manifestation differ in various areas. Different research method would lead to diverse accuracy even controversial conclusion. Thus we are still not sure about the association between MTHFD1 and NSCL/P and further exploration is needed. We also discussed this matter in our article.
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